HER2-positive breast cancer, an aggressive cancer, is treated with combinations of conventional anticancer drugs viz., cytotoxic drugs, nibs, and mAbs. Major limitations associated with this therapy are patient non-compliance due to the adverse drug reactions and rapid development of resistance by ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
曲妥珠单抗生物类似物:与新型研发的HER2靶向抗体不同,曲妥珠单抗生物类似物是由活细胞形成的生物制剂,具有与原产品相似的药代动力学和药效学特性。目前FDA批准了五种曲妥珠单抗生物类似物进入美国市场,其他药物正在开发中(见相关链接: https://www.fda.gov/dr...
[3] XU B, ZHANG Q, SUN T, et al. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial...
9. Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610-621. 10. Saura Manich C, O'Shaughnessy J, Aftimos PG, et al. LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing ...
Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin. Gastric Cancer Herceptin is approved in adults, in combinat...
Correspondence toFabio Puglisi MD, PhD. Rights and permissions Reprints and permissions About this article Cite this article Puglisi, F., Minisini, A.M., De Angelis, C.et al.Overcoming Treatment Resistance in HER2-Positive Breast Cancer.Drugs72, 1175–1193 (2012). https://doi.org/10.2165/11...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
In general, patients with HER2-positive breast cancer always receive combination therapy. In the early-stage setting, we are adding chemotherapy to anti-HER2 drugs and antibodies as previously discussed. In the metastatic setting, we are generally also using combination therapy. In the first-line ...
“I think this is a really important option for [estrogen receptor-positive] patients, along with endocrine therapy, to give them every change of remaining progression-free,” O’Shaughnessy concluded. REFERENCE O’Shaughnessy J. Managing New Drugs in Breast Cancer: Therapeutic Opportunities and ...